Risk for PML in Multiple Sclerosis Predicted With Anti-JCV Antibody Index
While an efficacious treatment for relapsing MS, natalizumab is associated with risk of developing progressive multifocal leukoencephalopathy.
The NDA resubmission is in response to the FDA's Complete Response Letter issued in 2011 which requested an improved understanding of the safety risks and overall benefit-risk profile.
The combination of genetics and exposure to organic solvents in paints and varnishes increases the risk of multiple sclerosis.
Brain volume loss has nonlinear dynamics and limited reproducibility as a marker of therapeutic response in multiple sclerosis.